TY - JOUR
T1 - Collagenous Gastritis
T2 - Characteristics and Response to Topical Budesonide
AU - Choung, Rok Seon
AU - Sharma, Ayush
AU - Chedid, Victor G.
AU - Absah, Imad
AU - Chen, Zongming Eric
AU - Murray, Joseph A.
N1 - Publisher Copyright:
© 2022 AGA Institute
PY - 2022/9
Y1 - 2022/9
N2 - Background and aims: Collagenous gastritis (CG) is a rare disorder characterized by subepithelial collagen deposition in the stomach. Standard medications have been only moderately successful in treating CG. We report results of a large, retrospective, open-label noncontrolled study of topical budesonide for CG, with an aim of establishing an alternative therapy for the disease. Methods: We identified patients treated for CG at Mayo Clinic (2000–2017) with topically targeted budesonide (TTB) in 2 formulations: open-capsule budesonide or compounded immediate-release budesonide capsule. Demographic, clinical, biochemical, and histologic variables were assessed for all patients before and after treatment. Results: We identified 64 patients with CG (50 adults, 14 children). Most were female (68%), mean age was 41 ± 22.8 years, and body mass index was 23.1 ± 5.9 kg/m2. In most pediatric patients, CG presented with abdominal pain and anemia; in adults, CG presented more often with weight loss (P < .001). Collagenous sprue or colitis were more common in patients >50 years of age (83%) vs those 19–50 years of age (27%) or <19 years of age (50%) (P < .001). Of the patients treated with TTB, 89% had a clinical response to TTB (42% complete, 46% partial), and 88% had a histologic response (53% complete, 33% partial). Conclusions: Adults and children with CG have a wide variety of symptoms, and notably, TTB therapy produced clinical and histologic improvement after other therapy had failed.
AB - Background and aims: Collagenous gastritis (CG) is a rare disorder characterized by subepithelial collagen deposition in the stomach. Standard medications have been only moderately successful in treating CG. We report results of a large, retrospective, open-label noncontrolled study of topical budesonide for CG, with an aim of establishing an alternative therapy for the disease. Methods: We identified patients treated for CG at Mayo Clinic (2000–2017) with topically targeted budesonide (TTB) in 2 formulations: open-capsule budesonide or compounded immediate-release budesonide capsule. Demographic, clinical, biochemical, and histologic variables were assessed for all patients before and after treatment. Results: We identified 64 patients with CG (50 adults, 14 children). Most were female (68%), mean age was 41 ± 22.8 years, and body mass index was 23.1 ± 5.9 kg/m2. In most pediatric patients, CG presented with abdominal pain and anemia; in adults, CG presented more often with weight loss (P < .001). Collagenous sprue or colitis were more common in patients >50 years of age (83%) vs those 19–50 years of age (27%) or <19 years of age (50%) (P < .001). Of the patients treated with TTB, 89% had a clinical response to TTB (42% complete, 46% partial), and 88% had a histologic response (53% complete, 33% partial). Conclusions: Adults and children with CG have a wide variety of symptoms, and notably, TTB therapy produced clinical and histologic improvement after other therapy had failed.
KW - Budesonide
KW - Collagenous Gastritis
KW - Corticosteroids
UR - http://www.scopus.com/inward/record.url?scp=85124513769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124513769&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2021.11.033
DO - 10.1016/j.cgh.2021.11.033
M3 - Article
C2 - 34864160
AN - SCOPUS:85124513769
SN - 1542-3565
VL - 20
SP - 1977-1985.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 9
ER -